| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Division of Infection, Inflammation and Repair, School of Medicine, Southampton General Hospital, Southampton, 2 Britannia Pharmaceuticals Limited, Surrey and 3 Dept of Pharmacy and Pharmacology, University of Bath, UK
CORRESPONDENCE: K.S. Babu, Mailpoint 810, Level D, Centre Block, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK. Fax: 44 2380701771. E-mail: ksb@soton.ac.uk
Keywords: allergen provocation, asthma, asthmatic response, exogenous surfactant, Pumactant
Received: September 2, 2002
Accepted January 23, 2003
D.A.Woodcock is an employee of Britannia Pharmaceuticals Ltd, the manufacturer of Pumactant. In addition J.H. Conway and J.N.Staniforth are scientific advisors to Britania Pharmaceuticals Ltd. The other authors have no conflict of interest.
Allergen-induced inhibition of pulmonary surfactant in asthma may promote airway oedema and consequently potentiate the severity of the asthmatic response. A randomised, single-blind, cross-over study of an inhaled synthetic phospholipid dry-powder surfactant (Pumactant) was conducted in atopic, asthmatic subjects with previously documented early and late asthmatic responses (EAR and LAR) to an inhaled allergen. This was conducted to evaluate the role of exogenous surfactant administration on EAR and LAR. A total of seven subjects had complete evaluable data and received the full dose of Pumactant.
Asthmatic subjects inhaled two separate doses of 400 mg Pumactant prior to an allergen exposure. The first dose was administered 8 h in advance and the second dose 30 min in advance. The dosage occurred through a purpose-built administration device. This was followed by a standard bronchial-provocation test, and forced expiratory volume in one second (FEV1) was measured at regular intervals over a 10-h period.
Pumactant was well tolerated and, surprisingly, abolished the EAR but not the LAR in all seven subjects. The mean area under the curve between 0–2 h (EAR) following bronchial provocation test was 0.08 for the Pumactant treatment group (PT) and 13.29 for the no treatment (NT) group. The maximum drop in FEV1 for EAR was 4.19% and 23.98% in the PT and the NT group, respectively.
The demonstration of inhibition of the early asthmatic response by exogenous surfactant, provides the first evidence that pulmonary surfactant dysfunction may also contribute to the very early asthmatic response to allergen. Exogenous surfactant administration could serve as a useful adjunct in controlling the early allergen-induced symptoms in patients with allergic asthma.
This article has been cited by other articles:
|
|
 |
|
  G. Enhorning Surfactant in Airway Disease Chest, April 1, 2008; 133(4): 975 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Asquith, H. S. Ramshaw, P. M. Hansbro, K. W. Beagley, A. F. Lopez, and P. S. Foster The IL-3/IL-5/GM-CSF Common Receptor Plays a Pivotal Role in the Regulation of Th2 Immunity and Allergic Airway Inflammation J. Immunol., January 15, 2008; 180(2): 1199 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kendall Fine airborne urban particles (PM2.5) sequester lung surfactant and amino acids from human lung lavage Am J Physiol Lung Cell Mol Physiol, October 1, 2007; 293(4): L1053 - L1058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. McCoy, K. Fisher, J. Robichaud, A. J. Ryan, and R. K. Mallampalli Transcriptional Regulation of Lung Cytidylyltransferase in Developing Transgenic Mice Am. J. Respir. Cell Mol. Biol., September 1, 2006; 35(3): 394 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Hite, M. C. Seeds, D. L. Bowton, B. L. Grier, A. M. Safta, R. Balkrishnan, B. M. Waite, and D. A. Bass Surfactant phospholipid changes after antigen challenge: a role for phosphatidylglycerol in dysfunction Am J Physiol Lung Cell Mol Physiol, April 1, 2005; 288(4): L610 - L617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Baritussio Lung Surfactant, Asthma, and Allergens: A Story in Evolution Am. J. Respir. Crit. Care Med., March 1, 2004; 169(5): 550 - 551. [Full Text] [PDF]
|
|
|
|
|
|
V. J. Erpenbeck, A. Hagenberg, Y. Dulkys, J. Elsner, R. Balder, H. Krentel, M. Discher, A. Braun, N. Krug, and J. M. Hohlfeld Natural Porcine Surfactant Augments Airway Inflammation after Allergen Challenge in Patients with Asthma Am. J. Respir. Crit. Care Med., March 1, 2004; 169(5): 578 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.A. Hills Asthma: surfactant eliminates the early allergen-induced response Eur. Respir. J., January 1, 2004; 23(1): 179 - 179. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
